JP2024525800A5 - - Google Patents
Info
- Publication number
- JP2024525800A5 JP2024525800A5 JP2024502055A JP2024502055A JP2024525800A5 JP 2024525800 A5 JP2024525800 A5 JP 2024525800A5 JP 2024502055 A JP2024502055 A JP 2024502055A JP 2024502055 A JP2024502055 A JP 2024502055A JP 2024525800 A5 JP2024525800 A5 JP 2024525800A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- nucleotide
- seq
- sirna
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110807464.3 | 2021-07-16 | ||
| CN202110807464 | 2021-07-16 | ||
| PCT/CN2022/103049 WO2023284559A1 (zh) | 2021-07-16 | 2022-06-30 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525800A JP2024525800A (ja) | 2024-07-12 |
| JP2024525800A5 true JP2024525800A5 (https=) | 2025-07-03 |
Family
ID=84919019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024502055A Pending JP2024525800A (ja) | 2021-07-16 | 2022-06-30 | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240325428A1 (https=) |
| EP (1) | EP4372085A4 (https=) |
| JP (1) | JP2024525800A (https=) |
| KR (1) | KR20240034787A (https=) |
| CN (2) | CN117580953B (https=) |
| AU (1) | AU2022309416A1 (https=) |
| CA (1) | CA3225015A1 (https=) |
| MX (1) | MX2024000650A (https=) |
| TW (1) | TW202321450A (https=) |
| WO (1) | WO2023284559A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119421952A (zh) * | 2022-06-27 | 2025-02-11 | 大睿生物医药科技(上海)有限公司 | 抑制载脂蛋白C3表达的siRNA |
| WO2024188174A1 (zh) * | 2023-03-10 | 2024-09-19 | 苏州瑞博生物技术股份有限公司 | 一种药物组合物及其用途 |
| TW202508607A (zh) * | 2023-05-19 | 2025-03-01 | 大陸商北京炫景瑞醫藥科技有限公司 | 雙股寡核苷酸及其共軛物和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| US9023820B2 (en) * | 2009-01-26 | 2015-05-05 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein C-III expression |
| CN103380113B (zh) | 2010-11-15 | 2018-03-30 | 生命科技公司 | 含胺的转染试剂及其制备和使用方法 |
| AU2013299717B2 (en) | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| EP3564374A1 (en) * | 2013-06-21 | 2019-11-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| WO2015006740A2 (en) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| WO2015051366A2 (en) * | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
| US20170051286A1 (en) * | 2014-05-01 | 2017-02-23 | Larry J. Smith | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT |
| EP3736334A1 (en) * | 2014-07-16 | 2020-11-11 | Arrowhead Pharmaceuticals, Inc. | Rnai compositions to treat apoc3-related diseases |
| CN107405358A (zh) * | 2015-02-27 | 2017-11-28 | Ionis制药公司 | 调节脂肪代谢障碍群体中的载脂蛋白c‑iii(apociii)表达 |
| CN120330183A (zh) * | 2017-06-02 | 2025-07-18 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| KR20240161202A (ko) * | 2017-09-11 | 2024-11-12 | 애로우헤드 파마슈티컬스 인코포레이티드 | 아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물 |
| EP3719127A4 (en) * | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE |
| DK3719128T3 (da) | 2017-12-01 | 2025-03-03 | Suzhou Ribo Life Science Co Ltd | Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf |
| AU2018394875B2 (en) | 2017-12-29 | 2023-08-03 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| WO2020135673A1 (zh) * | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| AU2020358016A1 (en) * | 2019-10-02 | 2022-04-21 | Dicerna Pharmaceuticals, Inc. | Chemical modifications of small interfering RNA with minimal fluorine content |
| CN112876534B (zh) * | 2019-11-29 | 2024-02-09 | 苏州瑞博生物技术股份有限公司 | 肝靶向化合物及缀合物 |
-
2022
- 2022-06-30 EP EP22841197.1A patent/EP4372085A4/en active Pending
- 2022-06-30 MX MX2024000650A patent/MX2024000650A/es unknown
- 2022-06-30 JP JP2024502055A patent/JP2024525800A/ja active Pending
- 2022-06-30 CA CA3225015A patent/CA3225015A1/en active Pending
- 2022-06-30 AU AU2022309416A patent/AU2022309416A1/en active Pending
- 2022-06-30 CN CN202280046072.2A patent/CN117580953B/zh active Active
- 2022-06-30 CN CN202511150352.XA patent/CN120989078A/zh active Pending
- 2022-06-30 WO PCT/CN2022/103049 patent/WO2023284559A1/zh not_active Ceased
- 2022-06-30 US US18/576,563 patent/US20240325428A1/en active Pending
- 2022-06-30 KR KR1020247004393A patent/KR20240034787A/ko active Pending
- 2022-07-15 TW TW111126698A patent/TW202321450A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525800A5 (https=) | ||
| JP2022544587A5 (https=) | ||
| JP2024528634A5 (https=) | ||
| Gryaznov | Oligonucleotide N3′→ P5′ Phosphoramidates and Thio‐Phoshoramidates as Potential Therapeutic Agents | |
| JP2019214587A5 (https=) | ||
| JP2021507686A5 (https=) | ||
| JP2021533804A5 (https=) | ||
| CA2453301A1 (en) | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | |
| CN105121452A (zh) | 三环核苷和由其制备的寡聚化合物 | |
| JP2024531728A5 (https=) | ||
| CN115335521B (zh) | 合成rna分子的方法 | |
| JP2002541825A (ja) | ユニバーサル及び／又は同義性塩基を含むアンチセンスオリゴヌクレオチド | |
| JP2023500661A5 (https=) | ||
| BR112020010090A2 (pt) | oligonucleotídeo gapmer, sal farmaceuticamente aceitável do mesmo, conjugado, composição farmacêutica e uso dos mesmos | |
| CN115698288A (zh) | 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 | |
| JP2026500220A (ja) | 高度ｒｎａ標的化（ａｒｎａｔａｒ） | |
| JP7793144B2 (ja) | 修飾ヘテロ核酸 | |
| BR112021001756A2 (pt) | oligonucleotídeos, oligonucleotídeo gapmer, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, usos de um oligonucleotídeo, método para o tratamento ou profilaxia de uma doença, processo para a fabricação de um oligonucleotídeo e invenção | |
| JP6882735B2 (ja) | 構造強化されたｍｉＲＮＡ阻害剤Ｓ−ＴｕＤ | |
| Osawa et al. | Oligonucleotide Synthesis and State-of-the-Art Drug Discovery | |
| JP5284084B2 (ja) | ねじれたインターカレーティング核酸（ｔｉｎａ）を用いた、フーグスティーン型の三重鎖および二重鎖の安定でそして選択的な形成、ならびにｔｉｎａの調製法 | |
| JP2025528464A (ja) | トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法 | |
| RU2024103826A (ru) | Нуклеиновая кислота, композиция и конъюгат, содержащие ее, а также способ ее получения и применение | |
| TW202309286A (zh) | 作為新穎基因靜默技術的非對稱短雙股ｄｎａ及其應用 | |
| TW202313977A (zh) | 作為新穎基因靜默技術的短雙股ｄｎａ及其應用 |